These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17233740)

  • 1. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
    Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
    Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
    Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
    Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells.
    Oyaizu N; Kayagaki N; Yagita H; Pahwa S; Ikawa Y
    Biochem Biophys Res Commun; 1997 Sep; 238(2):670-5. PubMed ID: 9299572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
    O'Connell J
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.
    Ottonello L; Tortolina G; Amelotti M; Dallegri F
    J Immunol; 1999 Mar; 162(6):3601-6. PubMed ID: 10092820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells.
    Fujino M; Li XK; Suda T; Hashimoto M; Okabe K; Yaginuma H; Mikoshiba K; Guo L; Okuyama T; Enosawa S; Amemiya H; Amano T; Suzuki S
    Xenotransplantation; 2001 May; 8(2):115-24. PubMed ID: 11328582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
    Matter-Reissmann UB; Sonntag KC; Gilli UO; Leguern C; Schneider MK; Seebach JD
    Xenotransplantation; 2004 Jan; 11(1):43-52. PubMed ID: 14962292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Fas ligand blocks destructive corneal inflammation in mouse models of corneal epithelial debridement and LPS induced keratitis.
    Gregory-Ksander M; Perez VL; Marshak-Rothstein A; Ksander BR
    Exp Eye Res; 2019 Feb; 179():47-54. PubMed ID: 30365944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
    Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling.
    Bremer E; Abdulahad WH; de Bruyn M; Samplonius DF; Kallenberg CG; Armbrust W; Brouwers E; Wajant H; Helfrich W
    Immunol Lett; 2011 Aug; 138(2):161-8. PubMed ID: 21514322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotactic activity of soluble Fas ligand against phagocytes.
    Seino K; Iwabuchi K; Kayagaki N; Miyata R; Nagaoka I; Matsuzawa A; Fukao K; Yagita H; Okumura K
    J Immunol; 1998 Nov; 161(9):4484-8. PubMed ID: 9794371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of IL-17 in Fas ligand-induced inflammation.
    Umemura M; Kawabe T; Shudo K; Kidoya H; Fukui M; Asano M; Iwakura Y; Matsuzaki G; Imamura R; Suda T
    Int Immunol; 2004 Aug; 16(8):1099-108. PubMed ID: 15237105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death.
    Nakano K; Saito K; Mine S; Matsushita S; Tanaka Y
    Apoptosis; 2007 Jan; 12(1):45-54. PubMed ID: 17136494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.